US protection ending in 2035: Bones, joints and muscles
As of the edition of 20 October 2026, 12 drugs have US protection that ends in 2035 in bones, joints and muscles; 6 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
12 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Bictegravir | Ends 2035 (patent) | Marketed | Gilead Sciences | 0 | |
| Bimekizumab | Ends 2035 (computed from the first US licence) | Marketed | UCB | IL17A, IL17F | 2 |
| Delandistrogene moxeparvovec | Ends 2035 (reference-product exclusivity) | Marketed | Avi Biopharma | 0 | |
| Efanesoctocog alfa | Ends 2035 (computed from the first US licence) | Marketed | Bioverativ Therapeutics | 0 | |
| Fruquintinib | Ends 2035 (patent) | Marketed | Takeda | FLT1, FLT4, KDR | 2 |
| Lenvatinib | Ends 2035 (patent) | Marketed | Eisai | FLT1, FLT4, KDR | 3 |
| Oritavancin | Ends 2035 (patent) | Marketed | Melinta Therapeutics | 0 | |
| Perflutren | Ends 2035 (patent) | Marketed | Lantheus Medical Imaging | 0 | |
| Rozanolixizumab | Ends 2035 (computed from the first US licence) | Marketed | UCB | FCGRT | 1 |
| Selinexor | Ends 2035 (patent) | Marketed | Karyopharm Therapeutics | XPO1 | 2 |
| Somatrogon | Ends 2035 (computed from the first US licence) | Marketed | Pfizer | GHR | 0 |
| Vosoritide | Ends 2035 (patent) | Marketed | Amicus Therapeutics | NPR2 | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2035 in bones, joints and muscles
In the product6 of these 12 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.